{"transactions":[{"id":1854299,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":112278,"kind":"person","name":"Kamarck Michael E.","position":1,"cik":"0001450730","reported_name":"Kamarck Michael E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-15T21:53:57.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date."}],"balance_after":15000,"derivative":{"exercise_price":53.08,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-037504","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000120919123037504/doc4.xml","form_type":"4"}},{"id":1854298,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":112278,"kind":"person","name":"Kamarck Michael E.","position":1,"cik":"0001450730","reported_name":"Kamarck Michael E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-15T21:53:57.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Common Stock underlying restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date."}],"balance_after":5625,"source":{"system":"sec-edgar","filing":"0001209191-23-037504","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000120919123037504/doc4.xml","form_type":"4"}},{"id":1876392,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":112278,"kind":"person","name":"Kamarck Michael E.","position":1,"cik":"0001450730","reported_name":"Kamarck Michael E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-05-26T16:31:58.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":21567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of:  (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2024 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":21567,"derivative":{"exercise_price":1,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":21567},"source":{"system":"sec-edgar","filing":"0001209191-23-032552","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1450730/000120919123032552/doc4.xml","form_type":"4"}},{"id":2211800,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":112278,"kind":"person","name":"Kamarck Michael E.","position":1,"cik":"0001450730","reported_name":"Kamarck Michael E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-07-06T20:32:03.000Z","date":"2022-07-05","kind":"grant","acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as of 1/36 of the total shares monthly beginning on July 5, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":48000,"derivative":{"exercise_price":2.48,"expiration_date":"2032-07-04","underlying":"Common Stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001209191-22-041401","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1450730/000120919122041401/doc4.xml","form_type":"4"}},{"id":2244715,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":112278,"kind":"person","name":"Kamarck Michael E.","position":1,"cik":"0001450730","reported_name":"Kamarck Michael E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-03T20:32:43.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 1, 2023 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date."}],"balance_after":18750,"derivative":{"exercise_price":22.7,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":18750},"source":{"system":"sec-edgar","filing":"0001209191-22-034067","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000120919122034067/doc4.xml","form_type":"4"}},{"id":2244714,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":112278,"kind":"person","name":"Kamarck Michael E.","position":1,"cik":"0001450730","reported_name":"Kamarck Michael E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-03T20:32:43.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Common Stock underlying restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 1, 2023 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date."}],"balance_after":3125,"source":{"system":"sec-edgar","filing":"0001209191-22-034067","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000120919122034067/doc4.xml","form_type":"4"}},{"id":2502697,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":112278,"kind":"person","name":"Kamarck Michael E.","position":1,"cik":"0001450730","reported_name":"Kamarck Michael E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-19T13:28:05.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."}],"balance_after":0,"derivative":{"exercise_price":14.77,"expiration_date":"2030-09-17","underlying":"Common Shares","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0001104659-21-141746","document":"tm2133436-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1450730/000110465921141746/tm2133436-6_4seq1.xml","form_type":"4"}},{"id":2531970,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":112278,"kind":"person","name":"Kamarck Michael E.","position":1,"cik":"0001450730","reported_name":"Kamarck Michael E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-29T22:11:16.000Z","date":"2021-10-27","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option shall vest over 36 months, 1/3 of which will vest on October 27, 2022 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date"}],"balance_after":30000,"derivative":{"exercise_price":22.02,"expiration_date":"2031-10-26","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-21-062119","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000120919121062119/doc4.xml","form_type":"4"}}]}